This alteration of EZH2 activity by ASCL1 was not unique to prostate cancer, but seems like a common effect of ASCL1 as observed in lung adenocarcinoma (Supplementary Fig. 5c) and SCLC (Supplementary Fig. 5h). This evidence concerns the gene EZH2 and lung adenocarcinoma.